000164545 001__ 164545
000164545 005__ 20240124105055.0
000164545 0247_ $$2pmid$$apmid:35606187
000164545 0247_ $$2doi$$a10.1016/j.biopsych.2022.02.010
000164545 0247_ $$2ISSN$$a0006-3223
000164545 0247_ $$2ISSN$$a1873-2402
000164545 0247_ $$2altmetric$$aaltmetric:127189480
000164545 037__ $$aDZNE-2022-01094
000164545 041__ $$aEnglish
000164545 082__ $$a610
000164545 1001_ $$00000-0001-7322-1195$$aEndres, Dominique$$b0
000164545 245__ $$aSpectrum of Novel Anti–Central Nervous System Autoantibodies in the Cerebrospinal Fluid of 119 Patients With Schizophreniform and Affective Disorders
000164545 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2022
000164545 3367_ $$2DRIVER$$aarticle
000164545 3367_ $$2DataCite$$aOutput Types/Journal article
000164545 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1706089803_14282
000164545 3367_ $$2BibTeX$$aARTICLE
000164545 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000164545 3367_ $$00$$2EndNote$$aJournal Article
000164545 520__ $$aAutoimmune psychosis may be caused by well-characterized anti-neuronal autoantibodies, such as those against the NMDA receptor. However, the presence of additional anti–central nervous system (CNS) autoantibodies in these patients has not been systematically assessed.MethodsSerum and cerebrospinal fluid (CSF) from patients with schizophreniform and affective syndromes were analyzed for immunoglobulin G anti-CNS autoantibodies using tissue-based assays with indirect immunofluorescence on unfixed murine brain tissue as part of an extended routine clinical practice. After an initial assessment of patients with red flags for autoimmune psychosis (n = 30), tissue-based testing was extended to a routine procedure (n = 89).ResultsBased on the findings from all 119 patients, anti-CNS immunoglobulin G autoantibodies against brain tissue were detected in 18% (n = 22) of patients (serum 9%, CSF 18%) following five principal patterns: 1) against vascular structures, most likely endothelial cells (serum 3%, CSF 8%); 2) against granule cells in the cerebellum and/or hippocampus (serum 4%, CSF 6%); 3) against myelinated fibers (serum 2%, CSF 2%); 4) against cerebellar Purkinje cells (serum 0%, CSF 2%); and 5) against astrocytes (serum 1%, CSF 1%). The patients with novel anti-CNS autoantibodies showed increased albumin quotients (p = .026) and white matter changes (p = .020) more frequently than those who tested negative for autoantibodies.ConclusionsThe study demonstrates five novel autoantibody-binding patterns on brain tissue of patients with schizophreniform and affective syndromes. CSF yielded positive findings more frequently than serum analysis. The frequency and spectrum of autoantibodies in these patient groups may be broader than previously thought.
000164545 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000164545 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000164545 650_7 $$2Other$$aAnti-neuronal autoantibody
000164545 650_7 $$2Other$$aAutoantibody
000164545 650_7 $$2Other$$aAutoimmune psychosis
000164545 650_7 $$2Other$$aBlood-brain barrier
000164545 650_7 $$2Other$$aCerebrospinal fluid
000164545 650_7 $$2Other$$aEndothelial cells
000164545 650_7 $$2Other$$aGranule cells
000164545 650_7 $$2Other$$aSchizophrenia
000164545 650_7 $$2NLM Chemicals$$aAutoantibodies
000164545 650_7 $$2NLM Chemicals$$aImmunoglobulin G
000164545 650_7 $$083869-56-1$$2NLM Chemicals$$aGranulocyte-Macrophage Colony-Stimulating Factor
000164545 650_2 $$2MeSH$$aAnimals
000164545 650_2 $$2MeSH$$aAutoantibodies
000164545 650_2 $$2MeSH$$aBrain
000164545 650_2 $$2MeSH$$aEndothelial Cells
000164545 650_2 $$2MeSH$$aGranulocyte-Macrophage Colony-Stimulating Factor
000164545 650_2 $$2MeSH$$aHumans
000164545 650_2 $$2MeSH$$aImmunoglobulin G
000164545 650_2 $$2MeSH$$aMice
000164545 650_2 $$2MeSH$$aMood Disorders
000164545 7001_ $$avon Zedtwitz, Katharina$$b1
000164545 7001_ $$aMatteit, Isabelle$$b2
000164545 7001_ $$0P:(DE-2719)9002228$$aBünger, Isabel$$b3$$udzne
000164545 7001_ $$0P:(DE-2719)2814341$$aFoverskov Rasmussen, Helle$$b4
000164545 7001_ $$aRunge, Kimon$$b5
000164545 7001_ $$00000-0002-9436-1258$$aFeige, Bernd$$b6
000164545 7001_ $$aSchlump, Andrea$$b7
000164545 7001_ $$aMaier, Simon$$b8
000164545 7001_ $$aNickel, Kathrin$$b9
000164545 7001_ $$aBerger, Benjamin$$b10
000164545 7001_ $$aSchiele, Miriam A.$$b11
000164545 7001_ $$00000-0001-7876-7779$$aCunningham, Janet L.$$b12
000164545 7001_ $$aDomschke, Katharina$$b13
000164545 7001_ $$0P:(DE-2719)2810931$$aPrüß, Harald$$b14
000164545 7001_ $$aTebartz van Elst, Ludger$$b15
000164545 773__ $$0PERI:(DE-600)1499907-9$$a10.1016/j.biopsych.2022.02.010$$gp. S000632232200097X$$n4$$p261-274$$tBiological psychiatry$$v92$$x0006-3223$$y2022
000164545 8564_ $$uhttps://pub.dzne.de/record/164545/files/DZNE-2022-01094_Restricted.pdf
000164545 8564_ $$uhttps://pub.dzne.de/record/164545/files/DZNE-2022-01094_Restricted.pdf?subformat=pdfa$$xpdfa
000164545 909CO $$ooai:pub.dzne.de:164545$$pVDB
000164545 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002228$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000164545 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814341$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000164545 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810931$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b14$$kDZNE
000164545 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000164545 9141_ $$y2022
000164545 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000164545 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000164545 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000164545 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-17$$wger
000164545 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-17
000164545 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-17
000164545 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-17
000164545 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-17
000164545 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-17
000164545 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBIOL PSYCHIAT : 2021$$d2022-11-17
000164545 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-17
000164545 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-17
000164545 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-17
000164545 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bBIOL PSYCHIAT : 2021$$d2022-11-17
000164545 9201_ $$0I:(DE-2719)1810003$$kAG Prüß$$lAutoimmune Encephalopathies$$x0
000164545 980__ $$ajournal
000164545 980__ $$aVDB
000164545 980__ $$aI:(DE-2719)1810003
000164545 980__ $$aUNRESTRICTED